Table 2. Clinical characteristics and HRPT2/CDC73 mutations in patients of parathyroid carcinoma.

Case no.	Gender	Historyof PHPT(year)	Age at diagnosis of PHPT/PC	#Size of tumor (cm)	*Serum Ca (mmol/L)	*PlasmaiCa(mmol/L)	*SerumP(mmol/L)	*SerumALP(U/L)	*Serum PTH(×UL)	Follow-upafter firstsurgery(year)	Distant metastasis	Recurrence	Kidneycysticlesions	Jawtumor	HRPT2mutation	Parafibrominstaining
ca1	Male	0.08	50/50	3.5	4.78	2.80	0.65	304	30.0	3.17	No	No	No	No	No	++
ca2	Male	1	36/45	NK	NK	NK	NK	NK	NK	11.00	Lung	Yes	NK	NK	No	–
ca3	Male	0.67	39/39	3.0	2.96	NK	0.74	1676	17.4	0.33	No	–	NK	NK	No	–
ca4	Female	0.5	71/71	2.5	3.50	1.71	NK	115	14.9	–	–	–	NK	NK	No	–
ca5	Male	0.25	58/58	1.5	4.66	2.06	0.33	91	17.1	3.25	No	Yes	No	No	Yes	+
ca6	Male	1	29/29	3.0	4.03	2.05	0.55	530	14.9	14.00	No	Yes	Yes	Yes	Yes	–
ca7	Male	3	41/41	3.5	4.28	2.31	0.87	945	47.2	0.25	No	–	No	No	No	–
ca8	Male	13	55/67	6.0	3.08	1.52	0.42	1087	16.8	13.00	No	Yes	No	No	Yes	+
ca9	Female	11	69/69	5.0	3.30	NK	0.55	NK	28.4	6.00	No	No	No	No	No	–
ca10	Male	1	40/40	NK	3.67	NK	NK	NK	NK	10.00	Lung	Yes	No	No	Yes	–
ca11	Female	0.25	24/30	3.0	3.85	NK	0.73	392	16.9	11.50	No	Yes	No	No	No	–
ca12	Male	0.17	60/60	NK	3.80	NK	0.50	662	20.0	1.67	Lung	Yes	Yes	No	Yes	+
ca13	Male	1	53/53	NK	4.13	NK	0.77	NK	NK	4.70	Lung, skeleton	Yes	No	No	Yes	+

^#size of the parathyroid tumor at the first surgery;

^*biochemical markers before the first surgery; NK: not known; UL: upper limit.